Spoke Chooses T IoT from T-Mobile and Deutsche Telekom to Pave the Way for Safer Cycling
13.7.2022 17:34:00 EEST | Business Wire | Press release
Today, T-Mobile (NASDAQ: TMUS) and Deutsche Telekom (NASDAQ: DTEGY) announced that Spoke, a mobility platform for safety, connectivity and rich rider experiences, will use T IoT to help bicyclists and motorists share the road more safely. T IoT, a comprehensive solution for global IoT connectivity, platform management and support, will power Spoke’s new hardware and software system that delivers near real-time information to bicyclists and motorists on the road, to help them reach their destination safely.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220712006196/en/
With T IoT, Spoke aims to improve awareness between bicyclists and motorists worldwide (Graphic: Business Wire)
According to the National Highway Traffic Safety Administration, 78 percent of bicycle accidents happen in urban areas where bicyclists ride near traffic. Spoke is on a journey to shrink those numbers by creating an ecosystem of IoT-connected sensors and cameras to provide bicyclists and motorists with highly accurate and timely alerts that will be delivered over LTE and 5G. This helps ensure that bicycles can “digitally” see cars, and more importantly, that cars can see bicycles.
Consider that there were nearly 50 million bicycles sold last year across the world. Then think about the millions of connected vehicles on roadways across the globe. Right now, the process of connecting vehicles to data requires the time-consuming, cumbersome process of enterprise negotiations with different network operators and IoT platforms. And bicyclists and motorists obviously don’t care how a safety notification is delivered or which jurisdiction they are in, as long as alerts are timely and actionable — because the outcome can oftentimes prevent property damage, injury, or ultimately save a life.
T IoT delivers network connectivity spanning the full range of technologies to support nearly every possible IoT scenario today, and tomorrow — including NB-IoT, LTE-M, LTE, and 5G — making it optimized to help deliver near real-time connectivity at scale, in 188 destinations worldwide.
“T IoT supports the low-latency speed and massive data required to connect Spoke’s global network of hardware and software on the road,” said Jarrett Wendt, CEO, Spoke. “As a result, Spoke will deliver much more than peace of mind for cyclists. It will deliver a world-class user experience with ride-enriching features made just for them — like traffic, navigation, ride and health information. T-Mobile and Deutsche Telekom’s leading innovation makes them the perfect teammate for Spoke’s solutions.”
“Spoke is exactly the kind of customer, innovation, and global application we had in mind when we launched T IoT earlier this year,” said Mishka Dehghan, Senior Vice President, Strategy, Product, and Solutions Engineering, T-Mobile Business Group. “Spoke is looking to leverage IoT and 5G for global good, and with T IoT, they will have one team and solution to manage all their connections around the world — to help the most vulnerable on our roadways by connecting them to the mobility ecosystem around them.”
“The future of our traffic system is based on a robust vehicle-to-everything (C-V2X) ecosystem provided through global cellular 5G connectivity. We are happy to support pioneers like Spoke and help building up a reliable connected system for mobility safety and rich rider experiences through our T IoT global footprint”, said Dennis Nikles, CEO of Deutsche Telekom IoT.
To learn more about T IoT from T-Mobile and Deutsche Telekom, go to: www.t-mobile.com/business/solutions/iot/T IoT-global
For more information about Spoke, visit: www.spokesafety.com
Qualifying service & devices required. Coverage not available in some areas.
About T-Mobile
T-Mobile U.S. Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile, Metro by T-Mobile and Sprint. For more information please visit: https://www.t-mobile.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712006196/en/
Contact information
Media Contacts
T-Mobile US, Inc. Media Relations
MediaRelations@t-mobile.com
Investor Relations Contact
T-Mobile US, Inc.
investor.relations@t-mobile.com
https://investor.t-mobile.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom